CAR T-Cell Therapy
THE ROLE OF the immune system in the development of cancers has been investigated for many years. Cancer cells can acquire changes that interfere with their detection by the immune system as well as promote changes that suppress the immune system. Over the past 15 years, many of the newer cancer therapies have focused on improving the immune system’s ability to detect and eliminate cancer cells. Immune approaches to cancer therapy have led the way in advances in oncology over the past year.
Among the novel immunotherapy approaches leading to FDA-approved therapies is the engineering of chimeric antigen receptors (CAR) on T cells to target neoplasms. This new therapeutic approach utilizes genetic engineering of T cells to stimulate immune responses that can eliminate the tumor cells.
Document Actions